vs
Side-by-side financial comparison of Celcuity Inc. (CELC) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $140.6M | ||
| Q3 25 | — | $131.9M | ||
| Q2 25 | — | $130.2M | ||
| Q1 25 | — | $114.5M | ||
| Q4 24 | — | $118.6M | ||
| Q3 24 | — | $115.9M | ||
| Q2 24 | — | $114.4M | ||
| Q1 24 | — | $96.8M |
| Q4 25 | — | $41.1M | ||
| Q3 25 | — | $19.1M | ||
| Q2 25 | — | $-980.0K | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | — | $15.2M | ||
| Q2 24 | — | $5.7M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
| Q4 25 | — | 26.4% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | — | -4.0% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 10.4% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | -4.8% |
| Q4 25 | — | 29.3% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | -0.8% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 5.0% | ||
| Q1 24 | — | -1.9% |
| Q4 25 | — | $0.50 | ||
| Q3 25 | — | $0.24 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $0.09 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $0.19 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $-0.02 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
